Artigo Acesso aberto

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

2020; American Association for Cancer Research; Volume: 11; Issue: 2 Linguagem: Inglês

10.1158/2159-8290.cd-20-1817

ISSN

2159-8290

Autores

Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed K. Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean‐Charles Soria, Gypsyamber D’Souza,

Tópico(s)

COVID-19 Clinical Research Studies

Resumo

Abstract Summary: Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

Referência(s)